<DOC>
	<DOCNO>NCT01380509</DOCNO>
	<brief_summary>The purpose study compare single-dose Bioavailability Kali G.D. Searle , Inc .</brief_summary>
	<brief_title>Bioavailability Study Metronidazole Capsules Under Fasting Conditions</brief_title>
	<detailed_description>To compare relative Bioavailability Metronidazole 375 mg Capsules Flagyl 375 mg Capsules healthy , adult subject fast condition</detailed_description>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Subjects meet follow criterion may include study Availability subject entire study period willingness adhere protocol requirement evidence informed consent form duly sign subject . Males female age 18 50 year body weight index ( BMI ) within 1930 ; demographic data ( sex , age , ethnic group , body weight , height smoke habit ) record report final report . Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance must record CRF ( laboratory test present section 7.1.3 ) Healthy accord laboratory result physical examination Subjects nonor exsmokers Significant history hypersensitivity metronidazole relate product well sever hypersensitivity reaction ( like angioedema ) drug . Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease . Females pregnant , lactate likely become pregnant study period . Females childbearing potential refuse use acceptable contraceptive regimen throughout study . Positive pregnancy test study . Presence history significant thyroid dysfunction ( hypo hyperthyroidism ) . Presence history significant hypoadrenalism . Presence history significant blood disorder ( thrombocytopenia , hemophilia , bleeding , etc. ) . Presence history significant neurological disorder . Maintenance therapy drug , significant history drug dependency , alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) , serious psychological disease . Any clinically significant illness previous 28 day day 1 study . Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc. ) . Participation another clinical trial previous 28 day day 1 study . Donation 500mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 5 day day 1 study . Positive urine screening drug abuse ( drug names present section 7.1.4. ) . Positive result HIV , HBsAg antiHCV test . History faint upon blood sampling .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bioequivalence , single-dose , fast</keyword>
</DOC>